Bristol Myers Squibb
Pharmaceuticals & BiotechnologyTransforming patients' lives through science — discovering, developing, and delivering innovative biopharmaceuticals.
Official Bristol Myers Squibb Careers Website
Quick Facts
- Headquarters
- Princeton, New Jersey, USA
- Founded
- 1887
- Employees
- 34,000+
- Valuation
- NYSE Listed (BMY) — ~$105B Cap
About Bristol Myers Squibb
Bristol Myers Squibb (BMS) is a global biopharmaceutical leader dedicated to discovering, developing, and delivering innovative medicines for serious diseases. Focus therapeutic areas include oncology, hematology, immunology, cardiovascular, and neuroscience.
BMS is famous for pioneering immuno-oncology therapies (Opdivo, Yervoy), CAR T cell therapies (Abecma, Breyanzi), and blockbuster cardiovascular treatments (Eliquis).
What Bristol Myers Squibb Does
Immuno-Oncology & Cancer Research
Pioneering immune-checkpoint inhibitor therapies and cell therapies designed to harness the body's immune system against cancer.
Hematology & CAR T Cell Therapy
Cellular immunotherapies and targeted agents treating multiple myeloma, lymphoma, and blood disorders.
Cardiovascular Medicines
Leading anticoagulants and novel cardiovascular therapies treating stroke, atrial fibrillation, and hypertrophic cardiomyopathy.
Immunology & Neuroscience
Targeted biologics treating plaque psoriasis, multiple sclerosis, inflammatory bowel disease, and neurodegenerative disorders.
Career Areas
Types of professional roles found inside Bristol Myers Squibb.
- Biomedical R&D & Discovery
- Clinical Development & Medical Affairs
- Cell Therapy Manufacturing
- Bioinformatics & Computational Genomics
Bristol Myers Squibb's History
- 1887Founding of Bristol-Myers
William McLaren Bristol and John Ripley Myers purchased Clinton Pharmaceutical Company in New York.
- 1989Merger of Bristol-Myers and Squibb
Merged with Squibb Corporation to create one of the world's largest pharmaceutical companies.
- 2019Acquisition of Celgene
Acquired Celgene for $74 billion, expanding leadership in oncology, hematology, and CAR T cell therapy.
- 2024Karuna Therapeutics Acquisition
Completed the $14B acquisition of Karuna Therapeutics, expanding into novel neuroscience and schizophrenia treatment.
Purpose & Values
“Transforming patients' lives through science”
